Glaxosmithkline Pharmaceuticals Ltd.

2170.80 +11.50 ▲0.5%

23 February 2024, 03:31:58 PM
Volume: 80,440

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.gsk-india.com
Market Cap 36,872.92 Cr.
Enterprise Value(EV) 35,488.53 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 31.22 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 69.71 Trailing Twelve Months Ending 2023-12
Industry PE 41.89 Trailing Twelve Months Ending 2023-12
Book Value / Share 93.58 Trailing Twelve Months Ending 2023-12
Price to Book Value 23.26 Calculated using Price: 2,176.60
Dividend Yield 1.47 Period Ending 2023-03
No. of Shares Subscribed 16.94 Cr. 169,406,034 Shares
FaceValue 10
About Glaxosmithkline Pharmaceuticals Ltd.
The company is engaged in research, manufacture and make available a broad range of medicines and vaccines that benefit people. The company's Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in anti-infectives and dermatology. Its R&D approach focuses on science related to the immune system, use of genetics and advanced technologies. Meanwhile, Its Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. The company is the leaders in India in the private segment.

Glaxosmithkline Pharmaceuticals Ltd. Delivery

Delivered Qty
Traded Qty

Glaxosmithkline Pharmaceuticals Ltd. Performance

1 Day
+0.53%
1 Week
-1.32%
1 Month
-4.36%
3 Month
+28.07%
6 Month
+54.87%
1 Year
+68.14%
2 Year
+42.30%
5 Year
+61.18%
10 Year
+43.38%

Glaxosmithkline Pharmaceuticals Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 24.95 18.75 16.08 17.26 21.22 4.71 17.42 18.39 27.58
Return on Capital Employed (%) 39.53 28.81 24.39 26.56 32.54 15.76 27.74 37.72 38.06
Return on Assets (%) 15.44 7.84 5.16 4.93 5.77 1.72 9.52 10.11 15.76

Glaxosmithkline Pharmaceuticals Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 1,829 2,183 2,007 2,057 2,140 1,821 1,478 2,663 1,741 1,540
Non Curr. Liab. 197 3,498 3,700 2,632 2,860 180 179 159 125 121
Curr. Liab. 1,107 784 881 2,949 2,804 1,022 1,355 1,698 1,326 1,462
Minority Int.
Equity & Liab. 3,133 6,465 6,588 7,639 7,804 3,023 3,012 4,520 3,193 3,123
Non Curr. Assets 546 4,087 4,753 4,103 4,445 1,248 809 812 699 623
Curr. Assets 2,587 2,372 1,833 3,531 3,356 1,775 2,023 3,708 2,494 2,499
Misc. Exp. not W/O
Total Assets 3,133 6,465 6,588 7,639 7,804 3,023 3,012 4,520 3,193 3,123

Glaxosmithkline Pharmaceuticals Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 3,363 2,838 2,908 2,871 3,128 3,224 2,926 3,278 3,252 3,311
Other Income 259 123 73 55 102 79 111 76 101 120
Total Income 3,622 2,961 2,982 2,926 3,230 3,303 3,036 3,354 3,352 3,432
Total Expenditure -2,788 -2,360 -2,489 -2,366 -2,527 -2,567 -2,327 -2,516 -2,447 -2,490
PBIDT 833 601 492 560 703 736 709 838 905 942
Interest 0 0 0 0 -1 -6 -4 -2 -2 -2
Depreciation -25 -25 -26 -38 -49 -83 -79 -68 -66 -69
Taxation -279 -202 -174 -189 -237 -213 -167 -398 -229 -207
Exceptional Items -52 2 46 18 29 -341 -173 12 -1 -136
PAT 476 376 337 351 445 93 287 381 608 529
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 476 376 337 351 445 93 358 1,695 611 529
Adjusted EPS 28 22 20 21 26 6 21 100 36 31

Glaxosmithkline Pharmaceuticals Ltd. Cash Flow

Particulars 10 years 2013-12 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 281 338 139 234 473 409 491 578 811 484
Cash Fr. Inv. 189 180 499 301 -104 -153 -57 418 -406 808
Cash Fr. Finan. -494 -497 -638 -511 -307 -358 -428 -696 -524 -1,543
Net Change -24 21 0 24 62 -102 6 300 -119 -251
Cash & Cash Eqvt 114 116 115 139 201 99 105 405 286 35

Glaxosmithkline Pharmaceuticals Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 75.00 75.00 75.00 75.00 75.00 75.00 75.00 75.00 75.00
Public 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Glaxosmithkline Pharmaceuticals Ltd. Announcements

Thu, 22 Feb 2024
Loss/Duplicate-Share Certificate-XBRL
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Loss of share certificates
Thu, 22 Feb 2024
Loss of Share Certificates
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Loss of Share Certificates
Wed, 21 Feb 2024
Analysts/Institutional Investor Meet/Con. Call Updates
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Transcript

Glaxosmithkline Pharmaceuticals Ltd. Technical Scans

Thu, 22 Feb 2024
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low

Glaxosmithkline Pharmaceuticals Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 373,756.40 1,561.25 +0.2%
Cipla Ltd. 117,370.75 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. 106,155.83 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. 97,309.86 6,774.05 +0.1%
Divi's Laboratories Ltd. 96,809.75 3,648.10 +0.1%
Zydus Lifesciences Ltd. 91,584.23 923.25 +2.1%
Torrent Pharmaceuticals Ltd. 88,295.34 2,626.95 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.97 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-12 31.65 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.30 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 123.28 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 70.00 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 30.80 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 59.10 2,626.95 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.99 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-12 4.53 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.95 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 14.41 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 7.43 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.71 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.35 2,626.95 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-03 0.02 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,626.95 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,626.95 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,626.95 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,626.95 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,561.25 +0.2%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,466.40 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,442.15 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,774.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,648.10 +0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 923.25 +2.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,626.95 +0.7%

Glaxosmithkline Pharmaceuticals Ltd. FAQ's

What is Glaxosmithkline Phar share price?

Can I buy Glaxosmithkline Phar shares now?

What is the Dividend Yield of Glaxosmithkline Phar?

What is the Market Cap of Glaxosmithkline Phar?

What are the key metrics to analyse Glaxosmithkline Phar?

What is the 52 Week High and Low of Glaxosmithkline Phar?

What is the trend of Glaxosmithkline Phar share price?